ROLE OF BMI, USE OF IMMUNE SUPPRESSANT AND PHARMACOKINETIC OF INFLIXIMAB-PATHWAY IN DETERMINING PROSPECTIVE AND RETROSPECTIVE RESPONSE TO THE DRUG IN COHORT OF IBD PATIENTS UNDER MAINTENANCE THERAPY WITH INFLIXIMAB.

Franco Scaldaferri  1     Daria D'Ambrosio  1     Diego Curro  2     Valentina Petito  3     Loris Riccardo Lopetuso     Lucrezia Laterza     Maria Teresa Pistone     Andrea Poscia     Silvia Pecere     Karl Florian Wintgens     Corinna Berger     Elisa Schiavoni     Giovanni Cammarota     Alessandro Milani     Antonio Gasbarrini    
1 Internal Medicine Department, Gastroenterology division,Catholic University of Sacred Heart of Rome,Rome,Italy
2 Pharmacology Departmente,Catholic University of Sacred Heart of Rome,Rome,Italy
3 Internal Medicine Department, Gas

Conference
UEG Week 2015

Citation
United European Gastroenterology Journal; 2015: 2 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing